Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting

A Spadaro, B Long, A Koyfman, J Perrone - The American journal of …, 2022 - Elsevier
Introduction Buprenorphine precipitated opioid withdrawal (BPOW) is an uncommon
complication of buprenorphine initiation in the emergency department (ED), but it can …

Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update

JM Leyrer-Jackson, AM Acuña… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Opioid use disorder (OUD) is characterized by compulsive opioid seeking and
taking, intense drug craving, and intake of opioids despite negative consequences. The …

The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health …

NA Livingston, M Davenport, M Head, R Henke… - Drug and alcohol …, 2022 - Elsevier
Abstract Background In March 2020, Veterans Health Administration (VHA) enacted policies
to expand treatment for Veterans with opioid use disorder (OUD) during COVID-19. In this …

Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach

KF Jones, M O'Reilly Jacob, J Spetz… - Journal of Nursing …, 2023 - Wiley Online Library
Introduction Drug overdoses have reached a historic milestone of over 100,000 deaths in a
single year, 75,673 related to opioids. The acceleration in opioid‐related deaths coupled …

Peer providers and linkage with buprenorphine care after hospitalization: a retrospective cohort study

HE Jack, ED Denisiuk, BA Collins… - Substance …, 2022 - journals.sagepub.com
Background: People with opioid use disorder (OUD) are increasingly started on
buprenorphine in the hospital, yet many patients do not attend outpatient buprenorphine …

Improving access to care via psychiatric clinical pharmacist practitioner collaborative management of buprenorphine for opioid use disorder

H Pals, J Bratberg - Journal of the American Pharmacists Association, 2022 - Elsevier
Background As the death toll continues to rise in the opioid overdose epidemic, increasing
access to medications for opioid use disorder (OUD), such as buprenorphine, is vital …

Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone

A Kline, JM Williams, ML Steinberg, D Mattern… - Journal of substance …, 2023 - Elsevier
Introduction Emerging data indicate a disproportionate increase in overdose deaths since
the onset of COVID-19. Speculation about causes for the increase center on rising drug use …

Suicide within 1 year of non-fatal overdose: Risk factors and risk reduction with medications for opioid use disorder

MA Nowels, PR Duberstein, S Crystal, P Treitler… - General hospital …, 2024 - Elsevier
Objective Individuals with substance use disorders and overdoses have high risk of suicide
death, but evidence is limited on the relationship between interventions following the initial …

Fibromyalgia is associated with increased odds of prior pain-precipitated relapse among non-treatment-seeking individuals with opioid use disorder

OT Hall, P Lagisetty, J Rausch, P Entrup… - Annals of …, 2024 - Taylor & Francis
Abstract Background/Objectives Chronic pain is an opioid use disorder (OUD) treatment
barrier and associated with poor outcomes in OUD treatment including relapse …

Rates of receiving medication for opioid use disorder and opioid overdose deaths during the early synthetic opioid crisis: a county-level analysis.

J Santaella-Tenorio, A Rivera-Aguirre, S Hepler… - …, 2024 - journals.lww.com
Background: Medications for opioid use disorder are associated with lower risk of drug
overdoses at the individual level. However, little is known about whether these effects …